title: Drugs that may harm bone: Mitigating the risk.
abstract: Glucocorticoids, proton pump inhibitors, selective serotonin reuptake inhibitors (SSRIs), certain antiepileptic drugs, and aromatase inhibitors have significant adverse effects on bone. Healthcare providers should monitor the bone health of patients on these agents, supplement their intake of calcium and vitamin D, encourage weight-bearing exercise, and initiate osteoporosis-prevention treatment as indicated.
authors.affiliation: Associate Professor of Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA. E-mail: hant@musc.edu.
authors.forename: Faye N
authors.initials: FN
authors.lastname: Hant
authors.affiliation: Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA.|Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Marcy B
authors.initials: MB
authors.lastname: Bolster
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects*; D002118:Calcium / Q000627:therapeutic use; D019587:Dietary Supplements; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control; D054328:Proton Pump Inhibitors / Q000009:adverse effects*; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D014807:Vitamin D / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D047072:Aromatase Inhibitors; D002118:Calcium; D005938:Glucocorticoids; D054328:Proton Pump Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors; D014807:Vitamin D; D014815:Vitamins